youtube_live
Q3 2026 earnings • released • EPS beat +26.81% • Revenue beat +60.98%
See resultschevron_right
ABCL:NASDAQ
AbCellera Biologics Inc
$12.50
arrow_upward
+5.22%(+0.62) 1D
$12.94
arrow_upward
+3.52% (+0.44)bedtimeAfter hours
Closed: Nov 9, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABCL...
Open
$11.90
High
$12.74
Low
$11.68
Mkt. cap
4.05B
Avg. vol.
4.53M
Volume
3.00M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.54
Beta
1.59
Shares outstanding
324.05M
No. of employees
562
Open
$11.90
High
$12.74
Low
$11.68
Mkt. cap
4.05B
Avg. vol.
4.53M
Volume
3.00M
52-wk high
$15.02
52-wk low
$2.74
EPS
-$0.54
Beta
1.59
Shares outstanding
324.05M
No. of employees
562
News stories
From web sources and news partners
GuruFocus
·
23 minutes ago
AbCellera Biologics (ABCL) Reports Promising Phase II Data and R
Yahoo Finance
·
3 hours ago
What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call
Investing.com
·
5 hours ago
Earnings call transcript: AbCellera beats Q3 2026 estimates as ABCL635 lifts shares
Benzinga
·
6 hours ago
AbCellera Biologics Q3 2026 Earnings Call Transcript
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth Care
Industry-
Websiteabcellera.com